Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110β protein levels in skeletal muscle of type 2 diabetic subjects

Diabetes

Volumn 51, Issue 2, 2002, Pages 443-448

  Kim, Young Bum ^a   Ciaraldi, Theodore P ^b,c   Kong, Alice ^b,c   Kim, Dennis ^b,c   Chu, Neelima ^b,c   Mohideen, Pharis ^b,c   Mudaliar, Sunder ^b,c   Henry, Robert R ^b,c   Kahn, Barbara B ^a,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; HEMOGLOBIN A1C; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; METFORMIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P110BETA; PROTEIN P85; TROGLITAZONE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLAMP; CONTROLLED STUDY; DIET RESTRICTION; DISEASE ASSOCIATION; ENZYME ACTIVITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERINSULINEMIA; INSULIN RELEASE; MALE; NEEDLE BIOPSY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; TREATMENT FAILURE; TREATMENT PLANNING; VASTUS LATERALIS MUSCLE;

EID: 0036068327     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.51.2.443     Document Type: Article

References (53)

1. The IRS-signaling system: A network of docking proteins that mediate insulin and cytokine action
2. Pathogenesis of type 2 diabetes: Metabolic and molecular implications for identifying diabetes
3. Phosphatidylinositol 3-kinase activation is required for insulin stimulation of pp70 S6 kinase, DNA synthesis, and glucose transporter translocation
4. Essential role of phosphatidylinositol 3-kinase in insulin-induced glucose transport and antilipolysis in rat adipocytes: Studies with a selective inhibitor wortmannin
5. Wortmannin inhibits the action of insulin but not that of okadaic acid in skeletal muscle: Comparison with fat cells
6. Roles of 1-phosphatidylinositol 3-kinase and ras in regulating translocation of GLUT4 in transfected rat adipose cells
7. Normal insulin-dependent activation of Akt/protein kinase B, with diminished activation of phosphoinositide 3-kinase, in muscle in type 2 diabetes
8. Insulin receptor sub-strate-1 phosphorylation and phosphatidylinositol 3-kinase activity in skeletal muscle from NIDDM subjects after in vivo insulin stimulation
9. New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers
10. Roles of PPARs in health and disease
11. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus
12. Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling
13. Troglitazone prevents glucose-induced insulin resistance of insulin receptor in rat-1 fibroblasts
14. Exercise and thiazolidinedione therapy normalize insulin action in the obese Zucker fatty rat
15. Metformin
16. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus
17. Metformin: A review of its metabolic effects
18. Association of metformin's effect to increase insulin-stimulated glucose transport with potentiation of insulin-induced translocation of glucose transporters from intracellular pool to plasma membrane in rat adipocytes
19. Mechanism of action of metformin: Insulin receptor and postreceptor effects in vitro and in vivo
20. Chronic insulin effects on insulin signalling and GLUT4 endocytosis are reversed by metformin
21. Glycemic effects of troglitazone versus metformin in poorly controlled type 2 diabetes mellitus patients
22. Intracellular glucose oxidation and glycogen synthase activity are reduced in non-insulin-dependent (type II) diabetes independent of impaired glucose uptake
23. Divergent regulation of Akt 1 and Akt2 isoforms in insulin target tissues of obese Zucker rats
24. Regulation of phosphatidylinositol 3-kinase activity in liver and muscle of animal models of insulin-resistant and insulin-deficient diabetes mellitus
25. Differential regulation of insulin receptor substrates-1 and -2 (IRS-1 and IRS-2) and phosphatidylinositol 3-kinase isoforms in liver and muscle of the obese diabetic (ob/ob) mouse
26. Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM
27. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone
28. Characterization of new oral antidiabetic agent CS-045: Studies in KK and ob/ob mice and Zucker fatty rats
29. Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat
30. Troglitazone effects on gene expression in human skeletal muscle of type II diabetes involve up-regulation of peroxisome proliferator-activated receptor-gamma
31. Troglitazone regulation of glucose metabolism in human skeletal muscle cultures from obese type II diabetic subjects
32. Thiazolidinediones (PPARgamma agonists) but not PPARalpha agonists increase IRS-2 gene expression in 3T3-L1 and human adipocytes
33. Regulation of gene expression by activation of the peroxisome proliferator-activated receptor gamma with rosiglitazone (BRL 49653) in human adipocytes
34. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats
35. Hyperglycemia decreases glucose uptake in type I diabetes
36. Effects of glycaemia on glucose transport in isolated skeletal muscle from patients with NIDDM: In vitro reversal of muscular insulin resistance
37. Glucose-induced phosphorylation of the insulin receptor: Functional effects and characterization of phosphorylation sites
38. Improved glucose tolerance restores insulin-stimulated Akt kinase activity and glucose transport in skeletal muscle from diabetic Goto-Kakizaki rats
39. 13C and 31P NMR studies on the effects of increased plasma free fatty acids on intramuscular glucose metabolism in the awake rat
40. Cellular mechanisms of insulin resistance
41. Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone
42. Mechanism of troglitazone action in type 2 diabetes
43. Reversal of chronic alterations of skeletal muscle protein kinase C from fat-fed rats by BRL-49653
44. Phorbol ester stimulates phosphorylation on serine 1327 of the human insulin receptor
45. PPARgamma, the ultimate thrifty gene
46. PPAR-γ: Adipogenic regulator and thiazolidinedione receptor
47. Metabolic and vascular effects of the thiazolidinedione troglitazone
48. Effect of metformin on peripheral insulin sensitivity in non insulin dependent diabetes mellitus
49. Metformin improves peripheral but not hepatic insulin action in obese patients with type II diabetes
50. Effect of metformin on insulin-stimulated glucose transport in isolated skeletal muscle obtained from patients with NIDDM
51. Irreversibility of the defect in glycogen synthase activity in skeletal muscle from obese patients with NIDDM treated with diet and metformin
52. Role of AMP-activated protein kinase in mechanism of metformin action
53. Cellular mechanism of metformin action involves glucose transporter translocation from an intracellular pool to the plasma membrane in L6 muscle cells